DoubleChecks

What was claimed

Pharmaceutical companies maintain a secret 'K-List' of patients more profitable dead than alive, calibrate chemo doses to not cure them, and engineer death on a schedule for billing optimization.

Our verdict

Inaccurate

No reputable investigation, regulator, or media outlet has documented a pharmaceutical- or hospital-run "K-List." Such a systematic secret list would be extraordinary and widely reported if it existed. Evidence-based oncology guidelines and research focus on balancing efficacy and toxicity, with dosing determined by clinical trials and regulatory review, not by intent to avoid cure. While some reporting criticizes high dosing and financial incentives around drug sales, no authoritative source supports the idea that companies deliberately set doses to prevent cure, and scientific guidance seeks optimal biological and clinical effect instead.

2 of 3 AI systems agree15 sources citedChecked Aug 23, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

Pharmaceutical companies calibrate chemo doses to not cure patients.

Incorrect97%
2 of 3 AIs agree·ChatGPT: Misleading

Pharmaceutical companies maintain a secret 'K-List' of patients more profitable dead than alive.

Incorrect97%
2 of 3 AIs agree·Perplexity: Can’t verify

Pharmaceutical companies engineer death on a schedule for billing optimization.

Incorrect97%
All 3 AIs agree

The overall claim reflects actual pharmaceutical industry practices

Misleading95%
1 AI checked

Verified against 15 sources

en.wikipedia.orgnyrequirements.combiopharmguy.comenglishdart.fss.or.krbiopharmguy.comandruswagstaff.comdrugdiscoverytrends.comvictag.org.aucnn.comwesthealth.orgbloomberg.comchemanalyst.comnature.commedika.lifeema.europa.eu

Detailed Analysis

The claim describes a very specific secret practice by pharmaceutical companies. No credible or authoritative sources support the existence of a K-List, profit-based death scheduling, or deliberately non-curative chemo dosing as described. Available evidence and discussions of pharma practices contradict these conspiracy-style allegations.

Why this verdict

  • The claim describes a very specific secret practice by pharmaceutical companies.
  • No credible or authoritative sources support the existence of a K-List, profit-based death scheduling, or deliberately non-curative chemo dosing as described.
  • Available evidence and discussions of pharma practices contradict these conspiracy-style allegations.

Claims checked

Pharmaceutical companies calibrate chemo doses to not cure patients.

Incorrect95%
Evidence-based oncology guidelines and research focus on balancing efficacy and toxicity, with dosing determined by clinical trials and regulatory review, not by intent to avoid cure. While some reporting criticizes high dosing and financial incentives around drug sales, no authoritative source supports the idea that companies deliberately set doses to prevent cure, and scientific guidance seeks optimal biological and clinical effect instead.

This claim may mislead readers without added context.

Pharmaceutical companies engineer death on a schedule for billing optimization.

Incorrect97%
There are no credible reports or regulatory findings that any pharmaceutical company intentionally times patient deaths for billing optimization. This is a conspiracy-style allegation that conflicts with the documented structure of drug approval, medical ethics, and oncology practice, and lacks any supporting evidence in reputable sources.

This claim may mislead readers without added context.

Pharmaceutical companies maintain a secret 'K-List' of patients more profitable dead than alive.

Can’t verify93%
There is no mention in credible sources of any secret 'K-List' used by pharmaceutical companies to track patients more profitable dead than alive. Discussions of "Big Pharma" conspiracy theories note allegations of concealment or profit-seeking but do not document such a list, indicating this is a conspiracy claim without evidence.

What other AI think

This statement makes multiple extreme accusations that are either completely unsupported or directly contradicted by evidence. No credible sources document a "K-List," and chemotherapy dosing is governed by established medical protocols designed to maximize cure rates, not minimize them. The claim represents dangerous conspiracy thinking without factual basis.

Why this verdict

  • This statement makes multiple extreme accusations that are either completely unsupported or directly contradicted by evidence.
  • No credible sources document a "K-List," and chemotherapy dosing is governed by established medical protocols designed to maximize cure rates, not minimize them.
  • The claim represents dangerous conspiracy thinking without factual basis.

Claims checked

Chemotherapy doses are calibrated to not cure patients

Incorrect98%
Medical evidence shows the opposite: chemotherapy dosing is carefully calibrated to maximize cure rates. Research demonstrates that dose reductions below standard levels significantly reduce cure rates, and protocols aim for optimal therapeutic effect.

This claim may mislead readers without added context.

Pharmaceutical companies maintain a secret 'K-List' of patients more profitable dead than alive

Incorrect99%
No credible evidence exists for any such list. While pharmaceutical companies do prioritize profits, documented concerns focus on pricing and access issues, not systematic patient elimination schemes.

This claim may mislead readers without added context.

Companies engineer death on a schedule for billing optimization

Incorrect99%
This describes a systematic murder scheme with no supporting evidence. Chemotherapy protocols are standardized by medical guidelines and regulatory bodies, not designed by pharmaceutical companies to kill patients on schedule.

This claim may mislead readers without added context.

The statement alleges a coordinated, industry-wide secret program to profit by killing patients. There is no credible evidence of a pharmaceutical- or hospital-run "K-List" that schedules patient deaths, though isolated criminal fraud and misconduct cases have occurred.

Why this verdict

  • The statement alleges a coordinated, industry-wide secret program to profit by killing patients.
  • There is no credible evidence of a pharmaceutical- or hospital-run "K-List" that schedules patient deaths, though isolated criminal fraud and misconduct cases have occurred.

Claims checked

Pharmaceutical companies maintain a secret 'K-List' of patients more profitable dead than alive.

Incorrect95%
No reputable investigation, regulator, or media outlet has documented a pharmaceutical- or hospital-run "K-List." Such a systematic secret list would be extraordinary and widely reported if it existed.

This claim may mislead readers without added context.

They engineer death on a schedule for billing optimization.

Incorrect95%
While perverse financial incentives and isolated fraud (billing schemes, overcharging, kickbacks) have been proven in prosecutions and settlements, no credible evidence supports coordinated "engineering" of patient deaths on a schedule for billing.

This claim may mislead readers without added context.

Pharma calibrate chemo doses to not cure patients.

Misleading90%
There are documented cases of individual wrongdoing (e.g., diluted or inappropriate dosing by pharmacists or rogue clinicians), but no evidence that manufacturers or the industry deliberately under-dose chemotherapy to avoid cures as a policy.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks